Minerva Neurosciences | NERV - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Adma Biologics USD 26.74M 5K 2026-06
ALKERMES USD 190.54M 6.1M 2026-09
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
AstraZeneca USD 4.07B 1.73B 2026-09
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.44M 5K 2026-06
CSL USD 1.23B 498M 2025-12
Eli Lilly USD 3.12B 305M 2026-09
GlaxoSmithKline GBP 2.16B 39M 2026-09
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 58.24M 1.24M 2026-09
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
J&J USD 6.25B 168M 2026-09
Merck USD 2.86B 25M 2026-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.28B 132M 2026-09
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.31B 325M 2026-09
Takeda JPY 271.71B 14.8B 2026-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12